登录

Happiness Biotech Announces $11 Million IPO in Nasdaq

作者: Mailman 2019-11-08 15:50
幸福来
http://www.fjxfl.com
企业数据由 动脉橙 提供支持
创新的营养保健品和膳食补充剂生产商 | PE | 运营中
中国-福建
2020-09-25
融资金额:$225万
查看

According to PR Newswire, Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced the closing of previously announced a U.S. underwritten initial public offering ("Offering") of 2,000,000 ordinary shares at a price to the public of $5.50 per share. The Company's shares commenced trading on the Nasdaq Capital Market on October 25, 2019, under the ticker symbol "HAPP".


The Company received aggregate gross proceeds of $11 million from this Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares at the public offering price, less underwriting discounts.


The Offering was conducted on a firm commitment basis. Univest Securities, LLC. acted as the lead underwriter, Aegis Capital Corp., Newbridge Securities Corporation, WestPark Capital, Inc. and Zinvest Global Limited acted as co-managers for the Offering. Hunter Taubman Fischer & Li LLC acted as counsel to the Company, and Ortoli Rosenstadt LLP acted as counsel to the underwriters in connection with the Offering.


Headquartered in Nanping, China, Happiness Biotech is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing, and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company's goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 SFDA registered "Blue-Cap" SKUs of nutraceutical and dietary supplements products. 


>>>>

About Univest Securities, LLC.


Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. It strives to provide clients with value-add service and focuses on building a long-term relationship with its clients. 

相关赛道 保健品及其它
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】全国首家HMOs产业化企业一兮生物获近亿元融资,加快推进工艺优化、管线开发

年产能将达200吨,这家合成生物学企业如何率先抢占HMO市场?

【首发】芝诺科技获超千万元人民币天使轮融资,布局合成生物学产品商业化落地

【首发】盈嘉合生完成数千万元A轮融资,加快在合成生物学领域的布局

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

博瑞医药今日登陆科创板,收盘大涨140.83%

2019-11-08
下一篇

Ping An Health Cloud Announces the Agreement to Buy 20% Stake of Hydee at ¥131M

2019-11-08